<DOC>
	<DOC>NCT00524329</DOC>
	<brief_summary>The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage (as determined by the treating physician).</brief_summary>
	<brief_title>Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage</brief_title>
	<detailed_description />
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>Patient with upper gastrointestinal complaints (defined as heartburn and/or regurgitation and/or nausea and/or bloated feeling)and treatment with esomeprazole 20mg once daily is started because of this (consult 1). Upper gastrointestinal complaints are thought to be related to NSAID use Patient is using an NSAID** with the following conditions: NSAID use has started at least one week before 1st consultation and is expected to be continued unchanged during the coming period (at least until consult 2) NSAID is taken at least 3 days a week (**)OTC or Prescription NSAID (**)Conventional NSAID or COX2 selective NSAID Use of a PPI and/or H2RA in the month preceding the study A history of reflux disease, not related to NSAID use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>upper GI-symptoms</keyword>
	<keyword>heartburn</keyword>
	<keyword>NSAID</keyword>
	<keyword>risk</keyword>
	<keyword>PPI</keyword>
	<keyword>Bloating</keyword>
	<keyword>Regurgitation</keyword>
</DOC>